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Title of review article 
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Abstract (195 words; limit 200) 
Purpose of review:  There are an increasing number of deaths among adult survivors of perinatal HIV.  
Multiple and complex factors drive this mortality, including problems with retention in care and adherence 
during adolescence, coupled with the critical period of transition from paediatric to adult care, increasing 
their risk of treatment failure and severe immunosuppression.  We reviewed studies which evaluated the 
impact of service delivery interventions to improve the health of perinatally infected adolescents living with 
HIV (P-ALHIV), to gain insight into what might help them survive the vulnerable period of adolescence. 
Recent findings:  Youth-focused health services and individual-level interventions may improve P-ALHIV 
adherence and retention in care.  However, there have been few studies, many with small sample sizes and 
with short durations of follow-up that end before the transition period.  Studies from other childhood-
onset chronic diseases are similarly limited. 
Summary: Further studies are urgently needed to identify optimal intervention strategies to reduce 
mortality and poor outcomes as the adolescent population expands and ages into adult care.  Until we have 
a more robust evidence base, programs can develop transition plans based on best practice 
recommendations, in order to optimise the health and longevity of ALHIV in adulthood.  
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Introduction 
Prevention of mother-to-child transmission (PMTCT) interventions and expansion of antiretroviral therapy 
(ART) coverage have led to a 58% decline in new HIV infections in children since 2000.[1]  However, there is 
broadening awareness of the increasing numbers of deaths among the generation of children who have 
survived to adolescence and adulthood with perinatal HIV.  This, together with failures to prevent new 
infections among young adults and link them successfully into care,[2, 3] has resulted in a serious youth-
centred threat to our achievements in controlling the HIV epidemic globally.  There are multiple and 
complex factors that drive HIV mortality in adolescents and young adults, but most paths eventually lead to 
poor adherence, causing treatment failure and severe immunosuppression. 
 
Interventions to promote adherence and retention which have been developed from experiences with HIV 
and other chronic diseases have the potential to push back against this wave of adolescent deaths.  In this 
paper we review studies which have evaluated the impact of service delivery interventions to improve the 
health of perinatally infected adolescents living with HIV (P-ALHIV).  While we focus primarily on studies 
targeting P-ALHIV who have had lifelong infection and as a result are likely to have more complex health 
needs, the interventions highlighted would potentially benefit the broader ALHIV population including 
behaviourally infected youth.  We also consider evidence from the wider literature among patients with 
other childhood-onset chronic illnesses on factors which could lead to improved outcomes in the period of 
paediatric to adult care transition for ALHIV. 
 
The global adolescent epidemic  
When characterizing adolescent HIV infections, treatment coverage, and associated mortality, there are 
varying ways that data for this age group have been analysed.  Global HIV surveillance estimates variably 
categorize adolescents (10-19 years) with children (<15 years), youth (15-24 years), and young adults (<25 
years).  At the end of 2013, there were 2.1 million adolescents living with HIV (ALHIV), 220,000 of whom 
had been newly infected that year.[4]  In 2014, there were 3.9 million youth with HIV, of whom 2.8 million 
were in sub-Saharan Africa.[5]  While the sex distribution is balanced among children aged <15 years living 
with HIV, almost two-thirds of all adolescents and youth with HIV are females, reflecting the highly inflated 
risk of HIV infection among adolescent girls.  Within current surveillance systems, we are unable to 
distinguish and estimate the proportion of the adolescent HIV population who are perinatally infected 
survivors.  
 
The World Health Organization reported that HIV had become the second leading cause of death for 
adolescents worldwide by 2012, and the fourth leading cause of disability-adjusted life-years lost, with 
broadly equal impact across males and females, [6] most likely driven by increased morbidity and mortality 
among P-ALHIV.  These findings were consistent with the Global Burden of Disease (GBD) Study which 
showed that HIV rose from the 101st cause of adolescent disability-adjusted life-years lost in 1990 to the 6th 
highest cause in 2013.[7]  These trends are primarily being driven by mortality within low- to middle-
income countries in Africa, but initial signals of these mortality trends are also emerging from high-income 
countries.[8, 9] 
 
Problems with adherence and poor clinic retention directly increase the risk of death from treatment 
failure and consequent opportunistic infections. There are indications from high-income countries that 
perinatally infected and behaviorally infected adolescents who are transitioning to adult HIV care are being 
lost to follow-up (LTFU) during this age period and defaulting from treatment.  Analyses of US national and 
international cohort data have described poorer outcomes among adolescents and young adults compared 
to older adults at every step of the treatment cascade, leading to viral suppression rates as low as 6-13%, 
and higher rates of death.[2, 3, 8, 10-12]  The US HIV Research Network reported that 20% of youth 
receiving HIV care at the age of 21 years were LTFU within one year.[13]  Similarly, young adults aged 15-24 
years in the UK, particular those with perinatal HIV, had much higher risk of LTFU compared to older adults 
and those infected through sex between men.[14]  Poorer adherence to treatment and mental health 
issues such as depression, addiction, and reactions to stigma have been identified as critical factors for 
higher LTFU and death, that have their roots in social marginalization as much as due to the virus itself.[15-
18]  These reversals in treatment success of perinatally nfected ALHIV are coming after a lifetime of effort 
to secure their survival across childhood.[19]  Thus more effective program-level strategies and youth-
focused interventions are urgently needed to support vulnerable adolescents during the transition into 
independent adult life and self-care.  
 
Interventions for young people with perinatal HIV 
We identified 12 studies which evaluated interventions to improve the adherence/ viral suppression[20-29] 
and retention of P-ALHIV (Table).[30, 31]  Four studies had randomised components,[20-22, 25], of which 
two were fully powered randomised controlled trials[20, 21] and two were pilots,[22, 25] four were 
prospective cohort studies,[23, 24, 26, 29] and four analysed routinely collected programme data collected 
at health facilities.[27, 28, 30, 31]  Two studies were multi-country; the remainder were conducted in the 
USA, Europe, Thailand and Kenya. The number of patients included in studies ranged from 9[28] to 730[30], 
and inclusion criteria varied by age.  Most studies included participants aged between 10 and 24 years,[20, 
21, 23-26, 29-31] and four studies including younger patients.[21, 22, 27, 28]  For ten studies, the majority 
of the participants had perinatal HIV, and in one study the proportion with perinatally acquired HIV was not 
stated.[30]  
 
Adherence interventions 
The two randomised controlled trials were individual-level interventions to improve adherence and viral 
suppression. The first, the “BREATHER” trial, evaluated the effect of weekends off therapy,[20] and the 
second, the “KONCERT” trial, compared outcomes of twice-daily versus once-daily lopinavir-containing 
regimens to reduce pill burden.[21]  The BREATHER trial randomised patients aged 8 to 24 years, who had 
good adherence (virological suppression for at least 12 months) on an efavirenz-containing regimen, to five 
days on and two days off ART, versus continuing on daily ART.[20]  At 48 weeks, there was no difference in 
the proportions which were virologically suppressed, demonstrating non-inferiority.  A qualitative sub-
study and pre- and post-trial questionnaires showed that young people expressed preference for the 
weekends off ART, particularly as it enabled weekend time with friends without thinking about treatments.  
In the KONCERT trial, children aged <18 years  were randomised to continue lopinavir/ritonavir twice-daily 
or change to once-daily.[21]  However, the once-daily arm failed to demonstrate non-inferiority in 
suppression of viral load. 
 
A further four studies applied individual level psycho-social interventions to ultimately improve adherence; 
there were a variety interventions, all involving sessions to explore knowledge about HIV and potential 
barriers to adherence,[22] health knowledge and coping skills, sexual risk reduction, and life goals,[23] and 
health empowerment.[24]  An additional study evaluated multi-systemic therapy which involved 
interventions to improve adherence at the individual, family and community levels.[25]  This therapy 
included, for example, cognitive behavioural therapy to reduce individual depressive symptoms, develop 
family routines such as set times to take medication , and working with families and healthcare providers to 
build positive working relationships.  All studies reported improvement in some outcomes in intervention 
groups compared to control groups.  For example, the largest of the four studies found that among Thai 
adolescents, knowledge and attitude scores about ART management, reproductive health, sexually 
transmitted infections, and risk behaviours, increased in the intervention group but not the control group, 
although the effect of increased knowledge on viral suppression was not evaluated.[23]  Similarly, 
adolescents in an outpatient unit in the USA who participated in multiple systemic therapy sessions had 
decreased viral load, although there was no difference in CD4 or self-reported adherence compared to a 
control group.[25] 
 
Three studies, two from the USA and one from the UK, implemented individual-level interventions among 
adolescents with suspected or documented adherence problems, but had no control groups.[26-28]  One 
study of 11 adolescents with very low CD4 counts (≤200c/mm3), who were off-ART despite multiple prior 
attempts to restart treatment, offered motivational interviewing combined with financial incentives.  The 
level of financial incentives was dependent on the extent of viral load decrease or sustained suppression 
over 12 months.[26]  Twenty-four months after enrolment, half of the participants had a viral load 
<50c/mL, and the mean CD4 gain was 122c/mm3, showing sustained longer-term impact.  The other two 
studies implemented inpatient directly observed therapy for patients with non-adherence.[27, 28]  The 
duration of inpatient stay for one study was seven days and reported no change in the subsequent viral 
load results of the nine patients.[28] In the second study, the mean duration of admission was 40 days, the 
19 patients had improved CD4 and viral load  at discharge and at six months post-discharge.[27] 
 
In terms of health service interventions, a French study implemented 90-minute peer support group 
sessions, once every six weeks for 26 months, in a paediatric outpatient department in Paris, to improve 
adherence.[29]  The sessions were led by two therapists trained in psychodynamic and family therapy and 
invited participants to determine their own themes for discussion.  After two years, worries about illness 
had decreased, with less negative perception about treatment among the intervention group receiving peer 
support.  However these outcomes increased or stayed the same among patients who declined the 
intervention or lived too far away to participate (p=0.026, p=0.030 respectively).  Additionally, the 
proportion with a viral load ≤200c/ml increased in the intervention group from 30% to 80% (p=0.063) but 
did not change in the other two groups (33% to 56% in the declined group and 50% to 50% in those living 
too far away).  Overall, the decrease in viral load was correlated with increased positive perceptions about 
ART treatment. 
 
Retention interventions  
There is growing recognition that barriers to the availability, accessibility and acceptability - of health 
services may affect the way that adolescents access health services, and that strategies are needed to 
develop HIV care services which are responsive to their needs.[32]  In Kenya, adolescent-friendly services 
were implemented at six health facilities, and were designed to improve retention in HIV care for both 
perinatally and behaviourally HIV-infected young people newly presenting to care.[30]  The adolescent-
friendly services comprised: training and mentorship for healthcare providers on care for adolescents; a 
dedicated adolescent clinic day at least once a month, providing integrated sexual and reproductive health 
services; and peer support groups and education programs.  Among newly enrolled patients yet to start 
ART, loss-to-follow-up over 12 months was 33% pre-implementation, falling to 22% post- implementation 
of adolescent friendly services.  Although this improvement was not statistically significant (p=0.15), and 
the follow-up time post-intervention was shorter than for the French study.[29]  For young people starting 
ART, loss to follow-up over six months pre-implementation was 12%, and 17% after (p=0.19).  In clinics 
without adolescent-friendly days, similar rates of loss-to-follow up were reported among young people yet 
to start ART (p=0.28), and significantly higher rates of losses among those starting ART in the post-
implementation period (p=0.04).  The  limited improvement in retention despite adolescent-friendly 
services may have been due to a number of factors such as high rates of migration and self-referrals to 
other clinics in this age group/region.[30] 
 
Another study examined whether the following components of care were adolescent-friendly across 12 
sites in the US: location of the clinic; waiting area; patient-provider communication modalities; 
appointment availability and scheduling; and types of providers caring for youth.  The investigators then 
analysed whether the availability of adolescent-friendly structures was associated with improved retention 
in care, defined as having two or more HIV care visits at least 90 days apart in a 12-month period.[31]  
Among young people aged 15 to 24 years, of whom a third were P-ALHIV, retention in care was better in 
youth attending clinics with an adolescent-friendly waiting area (adjusted odds ratio [aOR] 2.5, 95% 
confidence interval [CI] 1.1, 5.5), evening clinic hours (aOR 1.9, 95% CI 1.1, 3.3) and providers with training 
in adolescent health (aOR 2.0, 95% CI 1.0, 3.9).  These findings are in contrast to the Kenyan study; 
importantly, the two studies were conducted in settings with different social, cultural and resource 
contexts.  The observed variations in outcomes highlight the importance of conducting locally-appropriate 
research to evaluate and optimise interventions. 
 
Interventions in other childhood-onset chronic illnesses – what can we learn? 
We did not identify any studies which evaluated the effect of interventions on retention and outcomes in P-
ALHIV patients during the transition period from separate paediatric to adult HIV care settings.  This is a 
common model in middle- and high-income countries, and where we might expect the risk of loss to follow-
up to increase.[2, 33]  Recent systematic reviews on the impact of interventions in the transition period for 
adolescents with other childhood-onset chronic illnesses [34-37] have described poor outcomes after 
transition, including dramatic drops in attendance rates, and increased disease-related hospitalisations and 
complications.[38-40] 
 
Three systematic reviews[34, 35, 41] assessed the impact of transition interventions in adolescents across 
multiple chronic illnesses. An additional three reviews were disease-specific and related to interventions in 
adolescents with type-1 diabetes[37, 40] and congenital heart disease[38]. All studies included in the 
reviews were in high-income country settings and with participants ranging from 16 to 25 years.  The 
reviews focused on studies with discrete interventions around the time of transfer, with either a control 
group or a pre/post intervention study design, and included outcomes in adult care.  Across the six reviews, 
only four randomised studies were identified, all evaluating different educational interventions, with or 
without other features, to improve knowledge and self-management skills of adolescents in preparation for 
transition to adult care.[41]  The interventions were: a pilot comprehensive transition package, including a 
transition coordinator, for adolescents with type 1 diabetes,[42] a two-day workshop-based transition 
preparedness training for adolescents with spina bifida;[43] a nurse-led one on one teaching session for 
adolescents with heart disease;[44] and a web- and SMS-based education intervention for adolescents with 
a range of conditions.[45]  Findings suggested that three of the interventions may have slightly improved 
transitional readiness in young people.[43-45] 
 
The remaining studies reviewed largely included cohort data with historical controls or single cohorts with 
pre/post intervention outcomes.  One review highlighted how three of four studies which involved 
implementing dedicated adolescent-friendly young adult clinics, held on separate days from the general 
adult clinics, resulted in improved clinical outcomes.[34]  The same review showed that three of eight 
studies involving joint clinics across the transition period (attendance of staff from both services at one or 
more clinics, within either paediatric or adult services) had improved outcomes.[34]  One of these studies 
included over 1,500 youth with childhood-onset diabetes in multiple clinics across one province of Canada.  
Patients were categorised according to the diverse range of transition models that already existed across 
the various clinics.  After adjusting for all other factors, patients who had no change in their physician 
following transfer to adult care had a 77% reduced risk of diabetes-related hospital admissions in the two 
years post-transfer compared to those with a change in physician.[46] 
 
Such models of joint staffing during the critical period of transition need to be assessed in the adolescent 
HIV population, and may be particularly appealing in settings where dedicated young adult clinics are not 
feasible.  Indeed, a descriptive account of the transition experience of perinatal ALHIV in a hospital in 
northern Thailand suggests factors that may be key to their success.  These include an integrated approach 
involving paediatric and adult healthcare providers, respecting the individual patient’s readiness to 
transfer, and transitioning youth in groups so that there is a support system for the process.[47] 
 
Few studies have focused on the effect of age at transfer.  One study in patients with chronic kidney 
failure/transplant reported significantly increased mortality among those transferred to adult care at a 
younger age of <21 years versus those aged  ≥21 years, after adjusting for various demographic and clinical 
history factors.[48]  Although the study was not randomised, it nonetheless highlights the potential 
importance of age, maturity and readiness for transition to more independent, self-managed care.   This is 
an emerging area of research, with a number of studies assessing and validating tools to assess transition 
readiness.[49]  To date these studies have been limited to the North American setting and need to be 
tested and validated in other settings, age groups and chronic diseases.  If they are to be assessed in the 
ALHIV population, they would ideally be embedded in studies with long-term follow-up post-transfer, as 
this would allow evaluation of the effect of transition readiness with retention and treatment outcomes in 
adult care.  In addition, a number of the reviews highlighted concerns about lack of involvement of parents 
in a supportive capacity during transition, despite adolescents still being highly dependent on parents in 
most home life settings.[37, 38]  This may be particularly salient for P-ALHIV given the higher risk of 
orphanhood in this population compared to youth with other chronic diseases.[50]  Indeed, findings from a 
recent observational study in P-ALHIV reported a three-fold increased risk of viremia among adolescents 
when their parents were absent at the previous clinic visit, compared to adolescents whose parents were 
present.[51] 
 
The way forward 
Findings from these studies suggest that while youth-focused health services and individual-level 
interventions may improve ALHIV adherence and retention in HIV care, it is difficult to generalise their 
results due to the limited numbers of studies, sample sizes and short follow-up.[41]  Results from the 
BREATHER trial are encouraging and suggest that weekends off therapy are a viable option for adherent 
youth.  Psycho-social interventions and peer support may help to improve adherence, and there may be a 
role for financial incentives and directly-observed therapy in those with known or suspected adherence 
problems.  Although the KONCERT trial did not support routine use of once-daily lopinavir/ritonavir, long-
acting ART drugs are currently under development and may improve adherence to therapy and transform 
the way ART is delivered to patients struggling with daily adherence, including ALHIV.[52] 
 
Systematic reviews from other chronic disease areas similarly highlighted the need for more data and 
better quality studies, in particular randomised trials.  These would help us understand what intervention 
or combination of interventions around the time of transfer could have the greatest impact on improving 
short- and long-term retention and clinical outcomes in adult care, and, ultimately, survival.  Harmonisation 
of common outcomes of interest, such as retention, gaps in care, and adherence, would improve the ability 
to compare findings across models and settings.  Within the HIV field, such definitions could be shared in 
common resource areas, such as HICDEP (http://hicdep.org), an online platform for standardising data 
formats for collaborative analyses.  Also, most studies to date have been based in tertiary or specialist 
clinics, and there are limited data on those receiving care in primary care settings.  For primary care clinics 
there may be no change in location or the service provider team during transition to adult care, but rather a 
shift in focus from a child- to adult-focused health system.[35]  This is highly relevant for the majority of 
ALHIV residing in low- and middle-income country settings who may require alternative integrative models 
of transition preparation and support.  
 
There are emerging efforts to apply what has been learned in social protection research for youth 
prevention to the treatment arena.  A recent review summarises the evidence for the impact of cash 
transfers, parenting support and educational support on program outcomes for ALHIV.[53]  These offer a 
way in which individual and community level interventions can be supported or enhanced by interventions 
addressing wider socio-economic, structural and environmental constraints, to improve HIV treatment 
outcomes.  The use of novel technologies such as eHealth and social media may help improve how 
traditional healthcare systems reach and retain youth.[54]  Also, interventions which have been tested in 
adults living with HIV, and behaviourally infected adolescents, may have relevance to P-ALHIV, but were 
beyond the scope of this review. 
 
Whilst awaiting further studies on the determinants of successful transfer of care of ALHIV, what should 
programs do to help their own patients who have problems with adherence and retention, and may be at 
greater risk of dying?   Existing guidelines suggest the importance of early engagement and participation of 
youth and their families with both paediatric and adult healthcare teams, and individualised transition 
plans that prioritise youth-specific needs.  These approaches need to be situated within the context of 
health systems which themselves recognise the importance of transition pathways.[55-57]  Evaluation of 
individual programs would substantially strengthen the evidence base for what might work to retain ALHIV 
in care; it is likely there will be no “one size fits all” approach for ALHIV, and that interventions will need to 
take into account the specific needs of the clinic population to prevent morbidity and mortality over this 
vulnerable period of development. 
 
Key points 
 There are an increasing number of deaths in ALHIV, and those with perinatally acquired HIV may be 
at particular risk, especially during the period of transition to adult care 
 Problems with adherence and poor clinic retention are likely to be associated with higher mortality 
 Youth-focused interventions may improve P-ALHIV retention and adherence, but there are few 
studies and sample sizes tend to be relatively small; evidence from other chronic diseases is limited 
 In the absence of better evidence for how to successfully transition P-ALHIV, programs should 
follow transition guidelines to ensure individualised transition planning within current health 
system approaches 
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Table: Summary of studies describing the impact of interventions to improve P-ALHIV health outcomes 
Lead author, 
country, year 
Intervention Main 
outcome(s) 
Inclusion criteria Number 
receiving 
intervention 
Comparison Number 
receiving 
comparison 
Impact of intervention 
 
Individual level intervention, adherence outcome 
Butler, Europe, 
Thailand, 
Uganda, 
Argentina, USA, 
2011-2014[20] 
Randomisation to 
5 days on, 2 days 
off ART vs. 
continuous ART 
(“BREATHER” 
trial) 
Confirmed 
viral load 
(VL)>50c/ml 
by 48 weeks 
Patients aged 8-24 
years on efavirenz 
+ 2 NRTIs and VL 
<50c/ml for >12 
months 
99 Standard of care 
(continued daily 
ART) 
100 At 48 weeks: 
- 6 in the intervention 
arm v. 7 in control arm 
had confirmed 
VL>50c/ml (difference 
(90% CI) -1.2% (-7.3, 
4.9) 
PENTA, Europe, 
Thailand, South 
America, 2010-
2013[21] 
Randomisation to 
once daily vs. 
twice daily 
lopinavir/ritonavir 
(“KONCERT” trial) 
Confirmed VL 
≥50c/ml by 48 
weeks 
Patients aged <18 
years with weight 
≥15kg, and VL 
<50c/ml for at 
least 24 weeks on 
lopinavir/ritonavir-
containing ART 
86 Standard of care 
(twice daily 
lopinavir/ritonavir) 
87 At 48 weeks: 
- 12 in the intervention 
arm v. 7 in control arm 
had confirmed 
VL≥50c/ml (difference 
(90% CI) 6% (-2, 14)) 
Berrien, USA, 
2000-2001[22] 
Randomisation to 
8 structured 
home visits over 3 
months by a 
nurse, to improve 
knowledge of 
HIV, and identify 
real and potential 
barriers to 
adherence 
Knowledge 
and 
understanding 
about HIV and 
ART; self-
reported and 
pharmacy 
refill ART 
adherence 
All patients 
receiving care at a 
children’s hospital, 
age range 1.5 to 
20 years 
(presumed all P-
ALHIV) 
20 Standard of care 
medication 
adherence 
education, 
including a single 
home visit if ART 
adherence was 
poor 
17 At baseline there were 
no differences between 
groups in terms of HIV 
knowledge or 
adherence. 
Post-intervention: 
- the intervention group 
improved their 
knowledge score 
compared to the control 
group(p=0.02), but not 
their adherence score 
(p=0.07) 
- pharmacy adherence 
was better in 
intervention than 
control (p=0.002) 
- there were no 
differences in CD4 or VL 
Chokephaibulkit, 
Thailand, 2010-
2011[23] 
Two group and 
two individual 
sessions focusing 
on health 
knowledge, 
coping skills, 
sexual risk 
reduction, life 
goals 
Knowledge, 
attitudes and 
practices 
(KAP) scores 
between 
baseline and 2 
months post-
intervention 
P-ALHIV aged ≥12 
years 
107 Standard of care 32 At baseline there were 
no differences between 
groups in terms of KAP 
scores 
Post-intervention v. pre-
intervention: 
- knowledge scores 
increased for the 
intervention (p<0.01) 
but not control (p=0.15) 
groups 
-attitude scores 
increased for the 
intervention (p=0.03) 
but not control (p=1.0) 
groups 
- practice scores (% with 
desirable answers) did 
not increase in either 
group 
 
Individual level intervention, adherence outcomes, patients with known poor adherence 
Kaihin, Thailand, 
2011[24] 
Health 
empowerment 
intervention over 
5 sessions, within 
an 8 session 
intervention 
% with ART 
adherence 
≥95% of 
prescribed 
doses before 
and after the 
intervention 
Patients aged 15-
24 years (2/3 P-
ALHIV) with <95% 
adherence (based 
on pharmacy 
records) 
23 Standard of care 23 Baseline: 
- no one in either group 
had ART adherence 
≥95%. 
Post-intervention: 
- 82.6% of the 
intervention group and 
21.7% of the control 
group had adherence 
≥95% 
Letourneau, 
USA, (no year 
given)[25] 
Randomisation to 
multiple 
multisystemic 
therapy (MST) 
sessions over 6 
months for ART 
adherence 
problems 
Rate of 
change in VL, 
CD4 and 
medication 
adherence 
over 9 months 
Patients in 2 
paediatric clinics 
aged 9-17 years 
with adherence 
problems (33/34 
P-ALHIV) 
20 Standard of care 
(3 monthly clinic 
visits) plus one 
session of 
motivational 
interviewing 
14 Rate of change over 9 
months was: 
- VL: decreased in 
intervention but not 
control (p=0.008) 
CD4: no difference 
between groups 
(p=0.107) 
- adherence: no 
difference between 
groups (p=0.693). 
 
Individual level intervention, adherence outcome, patients with documented problems with adherence, no comparison group 
Foster, UK, 
2010-2011[26] 
ART restart, 
motivational 
interviewing, plus 
financial 
incentives 
dependent on VL 
reduction for 12 
months 
Median CD4 
and % 
VL<50c/mL at 
baseline and 
12 months, 
and 12 
months after 
cessation of 
financial 
incentives and 
motivational 
interviewing 
(end of study) 
P-ALHIV aged 16-
25 years, 
CD4≤200c/mm3, 
off ART despite 
multiple attempts 
11 None N/A* Median CD4 was: 
- 30 cells/mm3 at 
baseline 
- 140 cells/mm3 at 12 
months 
- 75 cells/mm3 at end of 
study 
 
VL was: 
- median 12,870c/mL at 
baseline 
- 5/11 had VL<50c/mL at 
12 months 
- 6/11 had VL<50c/ml at 
end of study 
Parsons, USA, 
2000-2003[27] 
Inpatient directly 
observed therapy 
(DOT) for ~40 
days 
Mean CD4 
and VL at 
admission, 
discharge, and 
6 months 
post-
P-ALHIV aged <18 
years who were 
hospitalised for 
adherence 
problems 
19 None N/A* Mean CD4 count (log 
viral load): 
- 262 (5.7) at admission 
- 492 (4.7) at discharge 
(p<0.001 and p<0.001 
respectively, v. 
discharge admission) 
- 429 (5) 6 months post-
discharge (p=0.01 and 
p<0.004 respectively, v. 
admission)) 
Glikman, USA, 
2004-2006[28] 
Inpatient directly 
observed therapy 
(DOT) for 7 days 
Change in VL 
between day 
1 and end of 
DOT, day 1 of 
DOT and 1st 
clinic visit 
post-DOT, and 
day 1 of DOT 
and 6 month 
post-DOT 
follow-up 
P-ALHIV aged 7 to 
17 years who were 
hospitalised for 
non-adherence 
9 patients 
with 13 
admissions 
None N/A* VL at end of DOT was 
lower than 1st day of 
DOT in 8 patients (mean 
decrease 0.8 (SD 0.55) 
log10 copies per mL), 
but there was no 
change in VL at post- 
DOT clinic appointments 
compared to 1st day of 
DOT. 
 
Health service intervention, adherence outcome 
Funck-Brentano, 
France[29] 
Peer support 
group sessions, 
90 minutes long, 
once every 6 
weeks, for 26 
months 
Emotional 
wellbeing; 
change in 
proportion 
with VL 
≤200c/ml 
between 
baseline and 
24 months 
P-ALHIV aged 12-
18 years 
10 a) Those declining 
to participate in 
the intervention 
b) Those living too 
far away from the 
clinic, so not 
invited to 
participate 
a) 10 
b) 10 
At 24 months: 
- worries about illness 
decreased in the 
intervention group, and 
stayed the same or 
increased for a) and b) 
- perceptions about 
treatment were less 
negative in the 
intervention group than 
a) or b) 
- the proportion with 
VL≤200c/ml increased 
in the intervention 
group from 30% to 80% 
(p=0.063), but did not 
change in a) or b) 
 
Health service intervention, retention outcome 
Teasdale, Kenya, 
2011-2013[30] 
Adolescent 
friendly services, 
including: training 
of healthcare 
providers; 
dedicated 
adolescent days 
with integrated 
services; peer 
support groups 
Incidence of 
pre-ART loss-
to-follow-up 
(LTFU) (not 
attending any 
visits within 
12 months) 
and post-ART 
LTFU (not 
attending any 
visits within 6 
months) pre-
intervention 
and post-
intervention 
Newly enrolled 
patients aged 10-
24 years, perinatal 
and behavioural 
HIV (proportion 
with perinatal HIV 
not stated) 
304 in pre-
ART 
comparison 
 
102 in post-
ART 
comparison 
The pre-
intervention 
period 
426 in pre-
ART 
comparison 
 
172 in post-
ART 
comparison 
Pre-ART LTFU was: 
- 33.2% at 12 months 
pre-intervention and 
25.2% post-intervention 
(p=0.15) 
 
Post-ART LTFU was: 
- 11.9% at 6 months 
pre-intervention and 
17.0% post-intervention 
(p=0.19) 
Lee, USA, 
2011[31] 
Components of 
clinics which were 
adolescent-
friendly, including 
waiting areas, 
evening clinic 
hours, and 
adolescent 
health-trained 
providers 
Completing ≥2 
primary HIV 
care visits ≥90 
days apart in 
a 12-month 
period 
15-24 year olds 
attending at least 
one clinic visit in 
12 sites (7 adult, 5 
paediatric) in 2011 
(35% P-ALHIV) 
680 None N/A* ALHIV were more likely 
to be retained in clinics 
with a youth-friendly 
waiting area (adjusted 
odds ratio (aOR) 2.5, 
95% confidence interval 
(CI) 1.1,5.5), evening 
clinic hours (aOR 1.9, 
95% CI 1.1, 3.3), and 
providers with 
adolescent health 
training (aOR 2.0, 95% 
CI 1.0, 3.9) 
Notes: 
* N/A, not applicable 
VL, viral load 
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